Degree of modulation of cell-surface CD3 by anti-lymphocyte therapies.
Henell
K R
KR
Department of Clinical Pathology, Oregon Health Sciences University, Portland.
Bakke
A
A
Kenny
T A
TA
Kimball
J A
JA
Barry
J M
JM
Norman
D J
DJ
D000911:Antibodies, Monoclonal / Q000276:immunology; D000937:Antigen-Antibody Reactions; D000945:Antigens, Differentiation, T-Lymphocyte / Q000032:analysis / Q000276:immunology*; D000961:Antilymphocyte Serum / Q000276:immunology; D017252:CD3 Complex; D004705:Endocytosis; D005434:Flow Cytometry; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D066298:In Vitro Techniques; D016030:Kidney Transplantation / Q000276:immunology; D016853:Muromonab-CD3; D016035:Pancreas Transplantation / Q000276:immunology; D011948:Receptors, Antigen, T-Cell / Q000032:analysis / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology*
D000911:Antibodies, Monoclonal; D000945:Antigens, Differentiation, T-Lymphocyte; D000961:Antilymphocyte Serum; D017252:CD3 Complex; D016853:Muromonab-CD3; D011948:Receptors, Antigen, T-Cell